SCN8A and epilepsy: To date, most identified human SCN8A-epilepsy associated mutations have been de novo amino acid substitutions, many of which are predicted or shown to have gain-of-function properties (Veeramah et al., 2012; Estacion et al., 2014; Liu et al., 2019; Heyne et al., 2020).